Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis

• Autores principales: Eduardo V. Mendes Roncada (Autor), Victoria Romanini Brambilla (Autor), Beatriz Freitas Filitto (Autor), Mariana Pirajá Genta (Autor), Marilda Ap. M. Morgado de Abreu (Autor)
• Formato: Libro
• Publicado: Karger Publishers, 2021-07-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

In the therapeutic arsenal to treat moderate to severe psoriasis, the new agents are secukinumab and ustekinumab, which are fully human monoclonal antibodies, directed against IL-17A and IL-12/23, respectively, which have been shown to be effective and safe in several studies. Their side effects are...